Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib in pediatric relapsed/refractory ALL or LLy
NCT03888534Phase 1Withdrawn
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants with Dose-limiting Toxicities During Reinduction Chemotherapy, Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events up to 30 months and 3 more. Planned start Oct 2020; status: withdrawn.
02
Drugs
ixazomib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT03888534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888534.